Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences

被引:70
作者
Amit, Doron [1 ]
Hochberg, Abraham [1 ]
机构
[1] Hebrew Univ Jerusalem, IL-91904 Jerusalem, Israel
来源
JOURNAL OF TRANSLATIONAL MEDICINE | 2010年 / 8卷
关键词
GROWTH-FACTOR-II; BACILLUS-CALMETTE-GUERIN; HEPATOCELLULAR-CARCINOMA; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; ONCOFETAL RNA; GENE-TRANSFER; TUMOR-MARKER; BREAST; PROSTATE;
D O I
10.1186/1479-5876-8-134
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The human IGF2-P4 and H19 promoters are highly active in a variety of human cancers (including bladder cancer), while existing at a nearly undetectable level in the surrounding normal tissue. Single promoter vectors expressing diphtheria toxin A-fragment (DTA) under the control regulation of IGF2-P4 or H19 regulatory sequences (IGF2-P4-DTA and H19-DTA) were previously successfully used in cell lines, animal models and recently in human patients with superficial cell carcinoma of the bladder (treated with H19-DTA). However this targeted medicine approach could be limited, as not all cancer patients express high levels of H19. Hence, a double promoter DTA-expressing vector was created, carrying on a single construct two separate genes expressing the diphtheria toxin A-fragment (DTA), from two different regulatory sequences, selected from the cancer-specific promoters H19 and IGF2-P4. Methods: H19 and IGF2-P4 gene expression was tested in samples of Transitional Cell Carcinoma (TCC) of the bladder by in-situ hybridization (ISH) and by quantitative Real-Time PCR (qRT-PCR). The therapeutic potential of the double promoter toxin vector H19-DTA-IGF2-P4-DTA was tested in TCC cell lines and in heterotopic and orthotopic animal models of bladder cancer. Results: Nearly 100% of TCC patients highly expressed IGF2-P4 and H19, as determined by ISH and by qRT-PCR. The double promoter vector exhibited superior tumor growth inhibition activity compared to the single promoter expression vectors, in cell lines and in heterotopic and orthotopic bladder tumors. Conclusions: Our findings show that bladder tumors may be successfully treated by intravesical instillation of the double promoter vector H19-DTA-P4-DTA. Overall, the double promoter vector exhibited enhanced anti-cancer activity relative to single promoter expression vectors carrying either gene alone.
引用
收藏
页数:18
相关论文
共 45 条
  • [1] The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma
    Ariel, I
    Sughayer, M
    Fellig, Y
    Pizov, G
    Ayesh, S
    Podeh, D
    Libdeh, BA
    Levy, C
    Birman, T
    Tykocinski, ML
    de Groot, N
    Hochberg, A
    [J]. JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 2000, 53 (06): : 320 - 323
  • [2] The product of the imprinted H19 gene is an oncofetal RNA
    Ariel, I
    Ayesh, S
    Perlman, EJ
    Pizov, G
    Tanos, V
    Schneider, T
    Erdmann, VA
    Podeh, D
    Komitowski, D
    Quasem, AS
    deGroot, N
    Hochberg, A
    [J]. JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (01): : 34 - 44
  • [3] Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma
    Ariel, I
    Miao, HQ
    Ji, XR
    Schneider, T
    Roll, D
    de Groot, N
    Hochberg, A
    Ayesh, S
    [J]. JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1998, 51 (01): : 21 - 25
  • [4] THE IMPRINTED H19 GENE AS A TUMOR-MARKER IN BLADDER-CARCINOMA
    ARIEL, I
    LUSTIG, O
    SCHNEIDER, T
    PIZOV, G
    SAPPIR, M
    DEGROOT, N
    HOCHBERG, A
    [J]. UROLOGY, 1995, 45 (02) : 335 - 338
  • [5] Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences
    Ayesh, B
    Matouk, I
    Ohana, P
    Sughayer, MA
    Birman, T
    Ayesh, S
    Schneider, T
    de Groot, N
    Hochberg, A
    [J]. MOLECULAR THERAPY, 2003, 7 (04) : 535 - 541
  • [6] Bae SK, 1999, CANCER RES, V59, P5989
  • [7] Cooper MJ, 1996, SEMIN ONCOL, V23, P172
  • [8] Davies JM, 2008, ONCOLOGY-NY, V22, P1470
  • [9] DIFFERENTIAL EXPRESSION OF THE HUMAN INSULIN-LIKE GROWTH FACTOR-II GENE - CHARACTERIZATION OF THE IGF-II MESSENGER-RNAS AND AN MESSENGER-RNA ENCODING A PUTATIVE IGF-II-ASSOCIATED PROTEIN
    DEPAGTERHOLTHUIZEN, P
    JANSEN, M
    VANDERKAMMEN, RA
    VANSCHAIK, FMA
    SUSSENBACH, JS
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 950 (03) : 282 - 295
  • [10] Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
    Dowsett, Mitch
    Dunbier, Anita K.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (24) : 8019 - 8026